コネチカット州における小細胞肺がんの臨床試験
コネチカット州内の拠点で、小細胞肺がんに関する9件の研究が参加者を募集しています。
コネチカット州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Yale University School of Medicine /ID# 278181, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07155174The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Yale Cancer Center/Clinical Trials Office, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07218146AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, New Haven
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Yale University Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- 他6件
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/30更新 · NCT06769126VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Hartford Hospital (site 210), Hartford
被験者募集中第1/2相
18歳〜80歳 · 全性別 · 2025/12/11更新 · NCT03556228ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。